| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
G. Walmsley Graham is Director at OLMA, with reported holdings spanning 3 companies. G. Walmsley Graham's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $11.6M at current prices.
Our model assigns G. Walmsley Graham a below-average insider score of 48/100, based on 4 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -12.2%.
G. Walmsley Graham's largest disclosed position is in OLMA as Director, worth about $10.4M. Net of sales, the OLMA filings show accumulation of 625,000 shares.
G. Walmsley Graham has 16 Form 4 filings on record from June 2020 to June 2026, across 3 companies: Director at Olema Pharmaceuticals (OLMA), 2020–2026; Director at AKRO, 2025; Director at Alx Oncology (ALXO), 2020–2021.
The 31 reported transactions were 11 option or other derivative awards, 10 open-market purchases, 4 dispositions back to the company and 3 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $53.7M and 2 sales worth about $22.2M.
The largest open-market purchase was 1,160,000 shares of OLMA at an average $19.00 on November 23, 2020, about $22.0M.
The largest open-market sale was 1,175,000 shares of OLMA at an average $14.85 on June 4, 2024, about $17.4M. Twelve months later OLMA was down 70%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | OLMA Olema Pharmaceuticals, Inc. | Director | Buy | 700,761 | $6.75 | $4,730,136.75 | +99.0% | -27.5% | +430.9% | |
| Dec 17, 2024 | OLMA Olema Pharmaceuticals, Inc. | Director | Sell | 700,761 | $6.75 | $4,730,136.75 | -100% | -27.5% | +430.9% | |
| Jun 4, 2024 | OLMA Olema Pharmaceuticals, Inc. | Director | Sell | 1,175,000 | $14.85 | $17,448,750.00 | -62.4% | -18.9% | -69.8% | |
| Dec 5, 2023 | OLMA Olema Pharmaceuticals, Inc. | Director | Buy | 640,000 | $10.74 | $6,871,279.47 | +55.2% | +12.8% | -21.8% | |
| Dec 14, 2020 | ALXO Alx Oncology Holdings Inc | Director | Buy | 20,000 | $76.00 | $1,520,000.00 | +2.1% | - | - | |
| Nov 23, 2020 | OLMA Olema Pharmaceuticals, Inc. | Director | Buy | 1,160,000 | $19.00 | $22,040,000.00 | New | - | - | |
| Jul 21, 2020 | ALXO Alx Oncology Holdings Inc | Director | Buy | 975,000 | $19.00 | $18,525,000.00 | New | - | - |